
Six NSW technology companies will share $7 million in funding under the first round of the state’s new Emerging Technology Commercialisation Fund, supporting projects spanning biotechnology, quantum sensing, advanced manufacturing, clean shipping and regional communications.
The inaugural recipients are Agscent, Celosia Therapeutics, Deteqt, Hullbot, Syenta and Zetifi.
The funding forms the first allocation from the $20 million, three-year Emerging Technology Commercialisation Fund, which is designed to help early-stage NSW companies move research and prototypes closer to commercial deployment.
Funding Targets Commercialisation Gap
The fund is aimed at companies that have progressed beyond an initial research idea but still need further development, testing, manufacturing or regulatory work before their technology can reach the market.
Businesses applying for the first round had to be headquartered in NSW, have annual revenue below $2.5 million and have more than 65 per cent of their full-time equivalent workforce based in the state.
Eligible technologies also needed to be at Technology Readiness Levels 3 to 7, broadly covering the stages between proof-of-concept and demonstration in a relevant environment.
Individual grants under the program range from $500,000 to $2 million.
Unlike many conventional grant programs, ETCF funding includes a repayment mechanism. Successful companies are required to begin repayments once their cumulative EBITDA from the time the grant was awarded exceeds $500,000, under conditions set out in their funding agreement.
Six Technologies Receive First-Round Support
The first six recipients cover a broad range of industries.
Agscent is developing a non-invasive breath test designed to detect Bovine Respiratory Disease within 60 seconds.
The technology is intended to help livestock producers identify disease earlier and begin treatment more quickly. The NSW Government estimates Bovine Respiratory Disease contributes around $60 million to $100 million in annual losses to the livestock industry.
Celosia Therapeutics is developing a potential disease-modifying treatment for amyotrophic lateral sclerosis and related neurodegenerative diseases, including motor neurone disease.
The technology remains under development, so its effectiveness as a treatment is not yet established.
Quantum Sensors and Cleaner Shipping
Deteqt is working on highly sensitive magnetic sensing technology with potential applications in maritime operations, navigation and mineral exploration.
The company is seeking to make advanced quantum sensing systems smaller, lower-cost and easier to deploy outside specialised research settings.
Sydney-based Hullbot is developing an autonomous system capable of cleaning ship hulls while vessels remain in the water.
Marine growth on hulls increases drag and can raise fuel consumption. Hullbot’s technology is intended to allow more regular cleaning, with the aim of reducing fuel use, operating costs and associated emissions.
The company is now looking to expand its existing hull-cleaning technology into larger shipping vessels.
Semiconductor Manufacturing and Regional Connectivity
Syenta will use the program to advance its Localised Electrochemical Manufacturing technology, which is being developed for next-generation semiconductor manufacturing.
The company says the process could support the production of higher-performance chips while potentially improving energy efficiency and expanding advanced manufacturing capability in Australia.
Regional technology company Zetifi is developing a vehicle-mounted smart antenna designed to improve connectivity in areas where conventional mobile coverage is limited.
The system is aimed at people working or travelling in regional and remote areas, including agricultural, emergency and other field-based operations.
Part of Broader NSW Innovation Strategy
The Emerging Technology Commercialisation Fund was launched in March 2026 as an initiative under the NSW Innovation Blueprint 2035.
It is intended to address a recurring commercialisation gap in which promising technologies can struggle to secure sufficient capital between early research and market deployment.
The program sits alongside other NSW technology and commercialisation initiatives, including the $150 million Science and Innovation Fund announced in September.
Projects supported through the ETCF can use funding for activities including prototyping, manufacturing and scale-up, trials, regulatory approvals, specialist equipment, intellectual property work and commercial feasibility studies.
Projects funded through the first round are expected to be delivered between January 2027 and December 2028.
Be the first to comment